These results demonstrate that sequential treatment of zorifertinib and third‐generation EGFR‐TKIs may be a better treatment option for patients with EGFR‐mutant NSCLC and untreated multiple BM, as zorifertinib is a high BBB penetrant and well‐validated EGFR‐TKI with T790M as the main resistant mutation, which is treatable with the third‐generation EGFR‐TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.